Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus Vitamin K1 in Advanced HCC
NCT02259647Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib + Vitamin K1 with Sorafenib + Placebo (2 arms). Primary endpoint: Overall Survival at 1 year. Started Oct 2014; status: completed.
02
Drugs
phytomenadione
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02259647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259647.